Shares of Bruker Corporation (NASDAQ: BRKR) tumbled 5.01% in pre-market trading on Monday following the release of its third-quarter 2025 financial results. Despite beating analyst expectations on both earnings and revenue, investors appeared concerned about the company's swing to a net loss and declining operating income.

The scientific instruments maker reported adjusted earnings per share of $0.45, surpassing the consensus estimate of $0.34. However, this represented a 25% decrease from $0.60 per share in the same quarter last year. Revenue came in at $860.5 million, slightly above analyst projections of $848.7 million, but still down 0.45% year-over-year.

Bruker's Q3 results revealed some concerning figures that likely contributed to the stock's decline. The company reported a net loss of $58.5 million, a significant downturn from positive earnings in the previous year. Operating income also turned negative, coming in at -$51.8 million. These figures suggest Bruker faced substantial challenges in maintaining profitability during the quarter, despite its revenue beat.

While specific guidance wasn't provided in the available news, Bruker did mention that its major cost-savings initiatives for FY2026 are progressing well towards the high end of the $100 million to $120 million cost-down targets. This could indicate that the company is actively working to improve its financial position, but investors may be concerned about the short-term impact on profitability.

The market's negative reaction to Bruker's earnings report highlights investor sensitivity to profitability metrics, even when top-line numbers exceed expectations. As the trading session progresses, analysts and investors will likely scrutinize the factors behind the company's net loss and assess its path to restored profitability in the coming quarters.